Abstract:Previous reports indicate a potential role for signal transducer and activator of transcription 3 (STAT3) in amyloid-β (Aβ) processing and neuritic plaque pathogenesis. In the present study, the impact of STAT3 inhibition on cognition, cerebrovascular function, amyloid pathology, oxidative stress, and neuroinflammation was studied using in vitro and in vivo models of Alzheimer's disease (AD)-related pathology. For in vitro experiments, human brain vascular smooth muscle cells (HBVSMC) and human brain microvascular endothelial cells (HBMEC) were used, and these cultured cells were exposed to Aβ peptides followed by measurement of activated forms of STAT3 expression and reactive oxygen species (ROS) generation. Further, 6 months old 5XFAD/APOE4 (5XE4) mice and age-matched negative littermates were used for in vivo experiments. These mice were treated with STAT3 specific inhibitor, LLL-12 for 2 months followed by neurobehavioral and histopathological assessment. In vitro experiments showed exposure of cerebrovascular cells to Aβ peptides upregulated activated forms of STAT3 and produced STAT3-mediated vascular oxidative stress. 5XE4 mice treated with the STAT3-specific inhibitor (LLL-12) improved cognitive functions and functional connectivity and augmented cerebral blood flow. These functional improvements were associated with a reduction in neuritic plaques, cerebral amyloid angiopathy (CAA), oxidative stress, and neuroinflammation. Reduction in amyloid precursor protein (APP) processing and attenuation of oxidative modification of lipoprotein receptor related protein-1 (LRP-1) were identified as potential underlying mechanisms. These results demonstrate the broad impact of STAT3 on cognitive functions, parenchymal and vascular amyloid pathology and highlight the therapeutic potential of STAT3 specific inhibition for treatment of AD and CAA.

Targeted Inhibition of STAT3 As a Potential Treatment Strategy for Atherosclerosis.

Tackling Myocardial Ischemic Injury: the Signal Transducer and Activator of Transcription 3 (STAT3) at a Good Site

Histone Deacetylase 3: A Potential Therapeutic Target for Atherosclerosis

The Role of JAK/STAT Signaling Pathway and Its Downstream Influencing Factors in the Treatment of Atherosclerosis

Protein Inhibitor of Activated Stat3 Suppresses Oxidized Ldl-Induced Cell Responses During Atherosclerosis in Apolipoprotein E-Deficient Mice

Genome-Wide Inhibition of Pro-atherogenic Gene Expression by Multi-STAT Targeting Compounds as a Novel Treatment Strategy of CVDs

Allosteric inhibitors of the STAT3 signaling pathway

Small Molecular Inhibitors and Degraders Targeting STAT3 for Cancer Therapy: an Updated Review (from 2022 to 2024)

STAT1 and IRF8 in Vascular Inflammation and Cardiovascular Disease: Diagnostic and Therapeutic Potential

Research Progress of STAT3-based Dual Inhibitors for Cancer Therapy.

Simultaneously Blocking ANGPTL3 and CD47 Prevents the Progression of Atherosclerosis Through Regulating Lipid Metabolism, Macrophagic Efferocytosis and Lipid Peroxidation

Targeting the KCa3.1 channel suppresses diabetes-associated atherosclerosis via the STAT3/CD36 axis

Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation

Role of PI3K in the Progression and Regression of Atherosclerosis

STAT3/miR-15a-5p/CX3CL1 Loop Regulates Proliferation and Migration of Vascular Endothelial Cells in Atherosclerosis

STAT3 inhibitor mitigates cerebral amyloid angiopathy and parenchymal amyloid plaques while improving cognitive functions and brain networks

Targeting angiopoietin-like 3 in atherosclerosis: From bench to bedside

Myricitrin attenuates endothelial cell apoptosis to prevent atherosclerosis: An insight into PI3K/Akt activation and STAT3 signaling pathways.

Structure, Function, Signaling Pathways and Clinical Therapeutics: the Translational Potential of STAT3 As a Target for Cancer Therapy

Revisiting Signal Transducer and Activator of Transcription 3 (STAT3) As an Anticancer Target and Its Inhibitor Discovery: Where Are We and Where Should We Go?

Research Progress of Mechanisms and Drug Therapy For Atherosclerosis on Toll-Like Receptor Pathway.